BiotechTube
Home/Acrivon Therapeutics/Rajshree Kandadai
RK

Rajshree Kandadai

Head of Business Development

Acrivon Therapeutics

Therapeutic Areas

Oncology

Acrivon Therapeutics Pipeline

DrugIndicationPhase
ACR-368 (Prexasertib)Platinum-Resistant Ovarian Cancer, Endometrial Cancer, Urothelial CarcinomaPhase 2
ACR-2316Advanced Solid TumorsPhase 1
ACR-6840Undisclosed Solid TumorsPreclinical

Leadership Team at Acrivon Therapeutics

PB
Peter Blume-Jensen
CEO, President, Founder, Chairperson
EG
Erick Gamelin
Chief Development Officer
KM
Kristina Masson
Co-Founder, EVP, Business Operations, Site Head, Director
JO
Jesper Olsen
Academic Co-Founder, Head of Phosphoproteomics
ED
Eric Devroe
Chief Operating Officer
MS
Michail Shipitsin
Head of Biomarker Development
JJ
Joon Jung
Head of Data Science
JV
John van Duzer
Head of Chemistry Manufacturing and Controls
TP
Thomas P. Nifong
Head of Clinical CDx Operations
SR
Sam Rua
Head of CDx Regulatory
View full Acrivon Therapeutics profile